Testosterone for low libido in postmenopausal women not taking estrogen.

@article{Davis2008TestosteroneFL,
  title={Testosterone for low libido in postmenopausal women not taking estrogen.},
  author={Susan R. Davis and Mich{\`e}le Moreau and Robin Kroll and C{\'e}line Bouchard and Nick Panay and Margery L. S. Gass and Glenn D Braunstein and Angelica Lind{\'e}n Hirschberg and Cynthia A. Rodenberg and Simon Pack and Helga Koch and Alain Moufarege and John W. W. Studd},
  journal={The New England journal of medicine},
  year={2008},
  volume={359 19},
  pages={
          2005-17
        }
}
BACKGROUND The efficacy and safety of testosterone treatment for hypoactive sexual desire disorder in postmenopausal women not receiving estrogen therapy are unknown. METHODS We conducted a double-blind, placebo-controlled, 52-week trial in which 814 women with hypoactive sexual desire disorder were randomly assigned to receive a patch delivering 150 or 300 microg of testosterone per day or placebo. Efficacy was measured to week 24; safety was evaluated over a period of 52 weeks, with a… 
Testosterone treatment of HSDD in naturally menopausal women: the ADORE study
TLDR
TTP was effective in treating HSDD and improving sexual function in this study of naturally menopausal women with and without concurrent hormone therapy.
Testosterone for low libido in postmenopausal women?
TLDR
The results of this trial confirm the improvement in sexual function for postmenopausal women seen in earlier studies using testosterone in combination with estradiol, implying thatEstradiol administration may not be essential for the beneficial effects of testosterone.
Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
TLDR
Randomized, double-blind, placebo-controlled studies have established the efficacy of the transdermal testosterone patch for relieving symptoms of HSDD in surgically and naturally menopausal women with and without concomitant estrogen or estrogen/progestin therapy.
The role of testosterone in menopausal hormone treatment. What is the evidence?
TLDR
Treatment with transdermal (patch) testosterone improved sexual function in several randomized controlled trials and women with hypoactive sexual desire disorder who were treated with testosterone reported more satisfying sexual episodes and sexual desire.
The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
TLDR
Based upon data from two recent clinical relevance studies, physicians can be reassured that postmenopausal women with HSDD report a meaningful benefit with testosterone therapy, and further, women will only continue therapy if they experience ameaning benefit.
Review: Testosterone therapy for reduced libido in women
  • R. Basson
  • Medicine
    Therapeutic advances in endocrinology and metabolism
  • 2010
TLDR
An increased frequency of satisfying sexual encounters and intensity of sexual desire and response has been shown in medically and psychiatrically healthy women able to have 2—3 satisfying sexual experiences each month before therapy commences.
Safety of testosterone use in women.
Female sexual desire appears to be in part androgen dependent, which has lead to the use of testosterone in women for low libido. Despite this benefit, the long-term safety of testosterone as a
Testosterone improves antidepressant-emergent loss of libido in women: findings from a randomized, double-blind, placebo-controlled trial.
TLDR
TT therapy resulted in a significant increase in the number of SSEs compared with Pl therapy in women with SSRI/SNRI-emergent loss of libido who need to remain on their antidepressant therapy, providing the first evidence that TT therapy may be a treatment option.
Effects of long-term testosterone administration in HIV-infected women: a randomized, placebo-controlled trial
TLDR
Long-term testosterone administration was well tolerated in HIV-infected women and resulted in significant improvements in body composition, bone mineral density, and quality of life indices.
Safety of testosterone therapy indicated for hypoactive sexual desire disorder in postmenopausal women
TLDR
Overall, there is still a lack of clarity on the safety of using testosterone therapy for HSDD in postmenopausal women and data from further studies are needed to draw a firm conclusion.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study
TLDR
Testosterone patch treatment increased the frequency of satisfying sexual activity and sexual desire, decreased personal distress, and was well tolerated in naturally menopausal women with hypoactive sexual desire disorder.
Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial.
TLDR
In surgically menopausal women with hypoactive sexual desire disorder, a 300 mug/d testosterone patch significantly increased satisfying sexual activity and sexual desire, while decreasing personal distress, and was well tolerated through up to 24 weeks of use.
Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial
TLDR
Transdermal testosterone therapy via a skin patch improved sexual desire and other sexual function domains and was well tolerated in these oophorectomized women with HSDD receiving concomitant transdermal estrogen.
Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.
TLDR
The 300-microg/d testosterone patch increased sexual desire and frequency of satisfying sexual activity and was well tolerated in women who developed hypoactive sexual desire disorder after surgical menopause.
Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder.
TLDR
In the Intimate SM 1 study, the testosterone patch improved sexual function and decreased distress in surgically menopausal women with HSDD and was well tolerated in this trial.
Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal Women
TLDR
The findings suggest that testosterone therapy may benefit women presenting with low libido in their late reproductive years, and several doses of testosterone, administered transdermally by a metered-dose spray system, in increasing self-reported sexual satisfaction among premenopausal women who had decreased sexual satisfaction.
Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder.
TLDR
Surgically menopausal women with HSDD in these studies received clinically meaningful benefits, including improvements in satisfying sexual activity, sexual desire, and personal distress.
Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality.
TLDR
It is concluded that in postmenopausal women, treatment with combined estradiol and testosterone implants was more effective in increasing bone mineral density in the hip and lumbar spine thanEstradiol implants alone.
The effects of postmenopausal hormone therapies on female sexual functioning: a review of double-blind, randomized controlled trials
TLDR
Double-blind randomized controlled trials of estrogen and/or testosterone on sexual function among natural or surgical menopause in women are reviewed and whether specific serum hormone levels are related to sexual functioning and how these group effects apply to individual women are unclear.
Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins.
TLDR
The postmenopausal use of oral estrogens in low doses favorably alters LDL and HDL levels that may protect women against atherosclerosis, while minimizing potentially adverse effects on triglyceride levels.
...
1
2
3
4
5
...